Results 231 to 240 of about 101,301 (311)

Distinct Gut-Brain Axis Dysregulation in Episodic Versus Chronic Migraine: Insights from NTG-Induced Mouse Models. [PDF]

Int J Mol Sci
Shin DC, Jung H, Park S, Song DG, Lee SH, Sohn JH.   +5 more
europepmc   +1 more source

Psychosocial factors as predictors of headache chronification: A systematic review and meta‐analysis of longitudinal studies

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study aimed to systematically review the literature and summarize, as well as quantitatively pool when feasible, longitudinal evidence regarding psychosocial predictors of headache chronification. Methods A comprehensive search was conducted in PubMed/MEDLINE, CINAHL, and PsycInfo.
Cornel H. M. Tol, Corine M. Visscher, Annemarie C. van der Wal, Naichuan Su, Hedwig A. van der Meer   +4 more
wiley   +1 more source

OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group. [PDF]

Toxins (Basel)
Argyriou AA, Dermitzakis EV, Chondrogianni M, Foska A, Rikos D, Xiromerisiou G, Soldatos P, Litsardopoulos P, Vikelis M, Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.   +9 more
europepmc   +1 more source

First successful protocol for desensitization to eptinezumab

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Background Eptinezumab is an anti‐calcitonin gene‐related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E–mediated, the team of Nice University Hospital (Nice, France) performed
Benoit Gerard, Hubert Praudel, Michel Lanteri‐Minet, Elise Van Obberghen, Fanny Rocher‐Moreau, Johanna Rousset, Ulysse Jacquier, Sylvie Leroy, Margot Delin   +8 more
wiley   +1 more source

Serum inflammatory cytokines as biomarkers for predicting chronic migraine transformation: a systematic review of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Syed EUR, Nazar N, Reddy NJ.
europepmc   +1 more source

OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open‐Label (COMPEL) trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Examine treatment responses to and safety of onabotulinumtoxinA for the preventive treatment of chronic migraine (CM) among diverse racial groups. Background Evidence suggests there are differences in headache treatment patterns, symptom profiles, and burden based on race.
Andrew M. Blumenfeld, Larry Charleston IV, Deena Kuruvilla, Belinda Savage‐Edwards, Richard B. Lipton, Ritu Singh, Patricia Jacob, Nicole A. Lawrence, Cuiwei Wang, Hope L. O'Brien   +9 more
wiley   +1 more source

OnabotulinumtoxinA Is an Effective Treatment for Reducing the Interictal Burden in Patients with Chronic Migraine: A Prospective Observational Study. [PDF]

Toxins (Basel)
Sánchez-Huertas A, Camejo-Mas O, Garcia-Roldan S, Alonso-Castillo R, Pulido-Fraiz L, Higuera Ruiz de la Hermosa A, Portocarrero-Sánchez L, Díaz-de-Terán J.   +7 more
europepmc   +1 more source

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

Beyond Headache: Non-cephalic Pain, Fatigue, and Post-Traumatic Stress Symptoms as Longitudinal Predictors of Chronic Migraine Outcomes. [PDF]

Pain Med
Sturgeon JA, Vest N, Barad M, Darnall B, Mackey S.   +4 more
europepmc   +1 more source

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the efficacy of cannabis for the treatment of acute migraine. Background Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.
Nathaniel M. Schuster, Mark S. Wallace, Thomas D. Marcotte, Dawn C. Buse, Euyhyun Lee, Lin Liu, Michelle Sexton   +6 more
wiley   +1 more source